Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontorpacept + Doxorubicin in Leiomyosarcoma
NCT04996004Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jun 2021
- Primary completion
- Dec 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of ontorpacept in leiomyosarcoma (LMS), sponsored by Pfizer. Started Jun 2021; status: terminated.
02
Drugs
ontorpacept
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NCT04996004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996004.